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• Adjuvant chemotherapy reduces the risk of distant recurrences in patients with high-risk, early- stage endometrial cancer with negative pelvic nodes.
• The sequential administration of adjuvant chemotherapy and radiotherapy achieves excellent local and distant control of disease in this clinical settings.
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Objectives. The purpose of this retrospective study was to assess the clinical outcome of patients with high-
risk, early-stage endometrioid endometrial cancer (stage Ib or II with myometrial invasion N50%, grade 2–3).
Methods. We assessed 192 patients who underwent hysterectomy, bilateral salpingo-oophorectomy and
pelvic lymphadenectomy, had histologically negative pelvic nodes, and had negative CT findings for aortic
node involvement.
Results. Tumor relapsed in 36 patients after a median time of 21.2 months. The recurrence was vaginal in 7
(19.4%), distant in 16 (44.4%), aortic in 8 (22.2%), and involved multiple sites in 5 (13.9%). There was a trend
to a lower vaginal recurrence rate in the 143 patients who received adjuvant radiotherapy (+chemotherapy)
comparedwith the 46who did not (2.1% versus 8.7%). Distant or aortic recurrenceswere lower in the 37 patients
who received adjuvant chemotherapy (+radiotherapy) than in the 152 who did not (2.7% versus 18.4%, p =
0.02). Of the 29 patients who received sequential adjuvant chemotherapy and radiotherapy, none developed
local recurrence and only one had distant recurrence. There was a trend for a better 5-year progression-free
survival and overall survival for the patients who received chemotherapy (+radiotherapy) compared with
those who did not (86.0% versus 71.3%, and 92.3% versus 75.6%, respectively).
Conclusions. Our data appear to suggest that adjuvant chemotherapy reduces the risk of distant or aortic
recurrences and that sequential adjuvant chemotherapy and radiotherapy achieve an excellent local and distant
control of disease in these clinical settings.
© 2014 Published by Elsevier Inc.
Introduction
Primary treatment of endometrial cancer is surgery, i.e. extrafascial
hysterectomy and bilateral salpingo-oophorectomy with or without
pelvic and para-aortic lymph node dissection via either laparotomy or
minimally invasive approach [1–4]. On the other hand, although the
performance of lymphadenectomy is required by the International
Federation of Gynecologic and Obstetrics [FIGO] staging system [5,6],
there is yet no consensus about whether and which kind of lymphade-
nectomy should be carried out in the surgical staging of thismalignancy
[7–12]. Outside clinical trials, this surgical procedure is usually
performed in women with poorly differentiated grade (G3) (assessed
on preoperative biopsy) and/or or deep myometrial invasion (assessed
on preoperative magnetic resonance imaging or intra-operative
sections). Of the 7990 surgically staged endometrial cancer patients
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reported in the FIGO Annual Report n. 26, 1054 patients had stage Ia
disease, 2833 had stage Ib (1988) disease, 1426 had stage Ic disease,
430 had stage IIa disease and 543 had stage IIb disease, and their
5-year overall survival rates were 90.8%, 91.1%, 85.4%, 83.3%, and
74.2%, respectively [5]. Survival of women with surgical stage I and II
endometrial cancer was strictly dependent on tumor grade. In fact,
5-year overall survival rates were 92.9% for patients with well differen-
tiated grade [G1] stage I disease, 89.2% for those withmoderately differ-
entiated grade [G2] stage I disease and 78.9% for those with poorly
differentiated [G3] stage I disease (hazard ratio [HR] = 2.8, 95% confi-
dence interval [CI] = 2.2–3.6), respectively. In the same series, 5-year
overall survival rates were 86.0% for patients with G1 stage II disease,
80.0% for those with G2 stage II disease, and 66.0% for those with G3
stage II disease (HR = 2.3, 95% CI = 1.4–3.5). The FIGO staging system
has been updated in 2009 [6].
The role of adjuvant treatment in early stage endometrial cancer is
still to be defined [13]. External beam pelvic irradiation [EBRT] signifi-
cantly reduces the risk loco-regional recurrence, without any significant
impact on cancer-related deaths or overall survival [14–21]. Although
recurrent disease occurs in less than 20% of patients with clinically
early endometrial cancer, most of these failures involve distant sites.
Postoperative platinum-based chemotherapy reduces the risk of
developing the first recurrence outside the pelvis [22–24], and the
pooled analysis of two randomized clinical trials (NSGO-EC-9501/
EORTC-55991 and MANGO ILIADE-III) has shown that the addition of
adjuvant chemotherapy to radiotherapy improves progression-free
survival in operated endometrial cancer patients with no residual
tumor and a high-risk profile [25]. However most studies comparing
adjuvant chemotherapy versus adjuvant radiotherapy or sequential
adjuvant chemotherapy and radiotherapy versus adjuvant radiotherapy
included heterogenous groups of women, i.e. both patients with stage
I–II disease with deep myometrial invasion and G3 grade and those
with advanced stages of disease.
The aim of this retrospective study was to assess the adjuvant treat-
ment and the pattern of failures of patientswith high-risk, surgical stage
Ib–II endometrioid-type endometrial cancer.
Materials and methods
This retrospective investigation assessed192patientswhounderwent
peritoneal washing, standard extrafascial (Piver–Rutledge class I) or
modified radical (Piver–Rutledge class II) hysterectomy, bilateral
salpingo-oophorectomy and pelvic lymphadenectomy for FIGO stage
Ib, G2–3 endometrioid-type endometrial cancer or FIGO stage II, G2–3
endometrioid-type endometrial cancer with myometrial invasion
N50% at the Department of Gynecology and Obstetrics of the University
of Pisa, Turin and Brescia between 1991 and 2012. These patients
represented all women with these high-risk factors treated at our
centers during the time period. Eighteen patients underwent also aortic
lymphadenectomy. All the patients had histologically negative pelvic,
and, when removed, aortic nodes negative. The 174 patients who did
not undergo aortic lymphadenectomy had negative computed tomog-
raphy (CT) findings for node aortic involvement. Abdomen-pelvis CT
scan was performed two to three weeks before surgery, and aortic
nodes were defined negative when their short axes were b5 mm.
One hundred and forty-eight women were operated via laparotomy
and forty-four via minimally invasive approach (laparoscopy or
robotics). The patients who underwent laparotomic or laparoscopic
hysterectomywithout pelvic lymphadenectomy, thosewho underwent
vaginal hysterectomy, and those who had synchronous endometrial
and ovarian cancer were excluded from the present analysis.
The histological classification was performed according to World
Health Organization classification. The architectural grade was defined
as follows: G1, b5% of non-squamous or non-morular solid growth
pattern; G2, 6–50% of non-squamous or non-morular solid growth
pattern; and G3, N50% of non-squamous or non-morular solid growth
pattern. Notable nuclear atypia, inappropriate for the architectural
grade, raised the grade of G1 or G2 tumor by one.
Post-operative treatment was given without well-defined protocols
and was established on the basis of pathological findings on surgical
specimens, patient age and general conditions.
Some patients had been enrolled in randomized clinical trials com-
paring radiotherapy versus chemotherapy [22] or radiotherapy versus
sequential chemotherapy and radiotherapy [25]. Anyway, adjuvant
therapy has been changed in the different centers over long interval
time of the study. In particular chemotherapy has been increasingly
used after 2008.
EBRTwas performedwith a 15–18MV beam, and a 45–50.4 Gy dose
was given in daily fractions of 1.8 Gy in 5–6 weeks. The pelvic target
volume was outlined on a CT scan. When performed, 45 Gy para-
aortic irradiation was planned in daily fractions of 1.8 Gy in 5 weeks.
Vaginal cuff high-dose rate brachytherapy (VBT) was added in selected
cases with isthmus or stromal cervical involvement after EBRT with a
cylinder applicator. The prescribed dose was 10–15 Gy in 5 Gy fractions.
Rectal and bladder doses were estimated from dose volume histograms
on CT-based plans and were evaluated to the dose points specified by
the International Commission on Radiation Units and Measurements
[26]. Adjuvant chemotherapy consisted of platinum-based regimens.
Radiotherapy was delivered sequentially after chemotherapy in
patients who received both adjuvant treatments.
Follow-up procedures are reported in a previous paper [27]. All the
patients but 3 have been periodically followed until September 2013
or until death.
The 3 patients lost to follow-up were excluded from recurrence and
survival analyses. The median follow-up of survivors was 57 months
(range, 9 to 225 months).
Statistical analysis
Patient age, FIGO substage, tumor grade, isthmus involvement, type
of radical hysterectomy and adjuvant treatment were analyzed for
association with recurrence risk, progression-free survival and overall
survival.
Peritoneal, hematogenous, and lymph node recurrences outside the
retroperitoneal area (i.e. inguinal,or axillary and supraclavicular) were
considered as distant failures. SAS statistical package (release 8.2; SAS
Institute, Cary, NC, USA) was used for the computations.
The rates of recurrences were compared to the explicative variables
using Pearson's χ2 test (or two-tailed Fisher's exact test when
appropriate).
The time from surgery to the detection of recurrence was defined as
progression-free survival. The time from surgery to death or last obser-
vation was defined as overall survival. The cumulative probability of
progression-free survival and overall survival was estimated by the
product-limit method. The log-rank test was used to compare the
homogeneity of progression-free survival and overall survival functions
across strata defined by categories of prognostic variables.
Results
Patient characteristics and adjuvant treatments are shown in
Table 1.
Ninety-four patients had G2 stage Ib disease, 65 had G3 stage Ib
disease, 14 had G2 stage II disease, and 16 had G3 stage II disease.
Surgical approach was open in 148, laparoscopic in 26, and robotic
in 18. Of the 192 patients, 38 had no further treatment, 127 had radio-
therapy only, and 37 had chemotherapy with or without radiotherapy.
Chemotherapy consisted in: i) carboplatin + paclitaxel (n. 3
patients) or cisplatin + cyclophosphamide (n. 4) or cisplatin +
epirubicin + paclitaxel (n. 1) for 6 cycles in the patients who had
chemotherapy only; ii) carboplatin + paclitaxel (n.12), cisplatin +
epirubicin/doxorubicin (n. 5) or cisplatin + epirubicin + paclitaxel
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(n. 1) for 4 cycles in the patients who had chemotherapy followed by
EBRT; and iii) carboplatin+ paclitaxel (n. 9) or single-agent carboplatin
(n. 2) for 4–5 cycles in the patients who had chemotherapy followed by
VBT.
Table 2 reported patient and tumor characteristics according to
postoperative treatment (no adjuvant treatment, radiotherapy only,
chemotherapy with or without radiotherapy). By the χ square test,
postoperative treatment was not related to patient age (χ2 = 3.45,
p = ns), isthmus involvement (χ2 = 4.84, p = ns) and tumor grade
(χ2 = 0.728, p = ns). Radiotherapy was more frequently used in
patients with FIGO stage II disease (χ2 = 6.14, p = 0.047). Therefore
the differences in treatment selection did not appear to influence the
outcome.
Tumour relapsed in 36 (19.0%) of 189 patients. Recurrence
developed within 12 months in 13 patients (36.1%), between 12
and 24 months in 9 (25.0%), and after 24 months in 14 (38.9%). The
median time to relapse was months 21.2 (range, 3–185 months). The
recurrence was vaginal in 7 (19.4%), distant in 16 (44.4%) (lung, 8;
peritoneum, 4; lung + peritoneum, 2; liver, 1; bone, 1), aortic in 8
(22.2%), and involved multiple sites in 5 (13.9%) (aortic nodes + liver,
1; pelvic nodes + peritoneum in 1; pelvic nodes + bone in 1; vagina +
pelvic nodes + lung in 1; vagina + lung in 1). No patients had an
isolated pelvic node recurrence.
There was a trend to a lower isolated vaginal recurrence rate in the
143 patients who received adjuvant radiotherapy (with or without
chemotherapy) compared with the 46 who did not (2.1% versus 8.7%,
p= 0.06) (Table 3).
Distant or aortic recurrences were significantly lower in the 37
patients who received adjuvant chemotherapy (with or without radio-
therapy) compared with the 152 patients who did not (2.7% versus
18.4%, p= 0.02) (Table 4).
Of the 29 patients who received sequential adjuvant chemotherapy
and radiotherapy, none developed local recurrence and only one
(3.4%) had distant recurrence.
Progression-free survival and overall survival were significantly
associated with patient age (p= 0.0025 and p= 0.0017, respectively),
FIGO stage (p= 0.035 and 0.0103, respectively), and isthmus involve-
ment (p= 0.0271 and 0.0280) (Table 5a and b).
There was a trend for a better 5-year progression-free survival and
5-year overall for the patients who received adjuvant chemotherapy
(with or without radiotherapy) compared with those who did not
(86.0% versus 71.3%, and 92.3% versus 75.6%, respectively) (Fig. 1). Con-
versely, adjuvant radiotherapy did not impact on progression-free sur-
vival and overall survival (Fig. 2).
Table 2
Patient and tumor characteristics according to postoperative treatment.
Variables Age FIGO stage Isthmus involvement FIGO grade
b64 ≥64 Ib II Yes not G2 G3
No therapy 38 pts 12 26 34 4 5 33 24 14
RT 114 pts 55 59 90 24 26 88 63 51
Chemotherapy + RT 37 pts 18 19 35 2 3 34 21 16
χ2, p value 3.45 ns 6.14 0.047 4.84 ns 0.728 ns
Legend: RT, radiotherapy.
Table 3
Isolated vaginal recurrence rate according to clinical–pathological variables and treatment
modalities (7 patients).
Variables Pts Recurrence P value
N N (%)
Age
b64 years 85 1 1.2 0.13
N64 years 104 6 5.8
FIGO stage
Ib 159 5 3.1 0.0006
II 30 2 6.7
FIGO grade
G2 108 3 2.8 0.46
G3 81 4 4.9
Isthmus involvement
Yes 34 2 5.9 0.61
Not 155 5 3.2
Type of hysterectomy
Type I 143 5 3.5 0.64
Type II 46 2 4.3
Adjuvant treatment
No further treatment 38 2 5.3
EBRT 102a 3 3.1
VBT 12 0 0
Chemotherapy 8 2 25
Chemotherapy + EBRT 18b 0 0
Chemotherapy + VBT 11 0 0
Adjuvant radiotherapy
No radiotherapyc 46 4 8.7 0.06
Radiotherapyd 143 3 2.1
Adjuvant chemotherapy
No chemotherapye 152 5 3.3 0.62
Chemotherapyf 37 2 5.4
Legend: EBRT, external beam radiotherapy; VBT, vaginal brachyterapy.
a VBT was added in 10 pts.
b VBT was added in 4 pts.
c Chemotherapy or no further treatment.
d With or without chemotherapy.
e Radiotherapy or no further treatment.
f With or without radiotherapy.
Table 1
Patient characteristics and postoperative adjuvant treatment.
Age (years) 64, median (range, 32–86)
FIGO stage
Ib 161
II 31
FIGO grade
G2 110
G3 82
Isthmus involvement
Yes 33
Not 159
Adjuvant treatment
No further treatment 38
EBRTa 105a
VBT 12
Chemotherapy 8
Chemotherapy + EBRTb 18b
Chemotherapy + VBT 11
Legend: G2, moderately differentiated; G3; poorly differentiated; EBRT, external beam
radiotherapy; VBT, vaginal brachytherapy.
a VBT was added in 11 pts.
b VBT was added in 4 pts.
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Discussion
An updated Cochrane systematic review of eight trials comparing
the efficacy and toxicity of adjuvant radiotherapy versus no treatment
in stage I endometrial cancer showed that EBRT significantly reduced
loco-regional recurrence compared with no EBRT (or VBT alone)
(HR = 0.36, 95%CI = 0.25–0.52, p b 0.001), without any improvement
in overall survival (HR = 0.99, 95% CI = 0.82–1.20), endometrial
cancer-specific survival (HR = 0.96, 95% CI = 0.72–1.28), or distant
recurrence rates (relative risk [RR] = 1.04, 95% CI = 0.80–1.35) [21].
EBRT was associated with an increased risk of severe acute toxicity,
severe late toxicity, and reduced quality of life. A prior meta-analysis
had led to similar conclusions, and had suggested that EBRT was
detrimental for low-risk endometrial cancer (stage Ia, G1–2) (odd ratio
[OR] for OS = 0.71; 95%CI = 0.52–0.96), did not affect overall survival
in intermediate risk disease (either stage Ia G3 or stage Ib G1–2) (OR =
0.97; 95%CI = 0.69–1.35), and offered a significant benefit in clinical
outcome in high-risk disease (stage Ib G3) (OR = 1.76; 95%CI = 1.07–
2.89) [19]. All the evidences point to the direction that patients with
low- and intermediate-risk disease do not benefit from adjuvant EBRT
and that, otherwise, high-risk patients could have some advantage.
The randomized PORTEC-2 trial compared adjuvant VBT versus EBRT
in 427 patients with high-intermediate risk endometrial cancer [28].
Table 4
Distant or aortic nodal recurrence rate according to clinical–pathological variables and
treatment modalities (29 patients a).
Variables Pts Recurrence P value
N N (%)
Age
b64 years 85 11 12.9 0.43
N64 years 104 18 17.3
FIGO stage
Ib 159 20 12.5 0.025
II 30 9 30.0
FIGO grade
G2 108 15 13.8 0.55
G3 81 14 17.2
Isthmus involvement
Yes 34 10 29.4 0.0018
Not 155 19 12.2
Type of hysterectomy
Type I 143 21 14.7 0.64
Type II 46 8 17.4
Adjuvant treatment
No further treatment 38 7 18.4
EBRT 102b 17 16.6
VBT 12 4 33.3
Chemotherapy 8 0 0
Chemotherapy + EBRT 18c 1 5.5
Chemotherapy + VBT 11 0 0
Adjuvant radiotherapy
No radiotherapyd 46 8 17.4 0.64
Radiotherapye 143 21 14.7
Adjuvant chemotherapy
No chemotherapyf 152 28 18.4 0.02
Chemotherapyg 37 1 2.7
Legend: EBRT, external beam radiotherapy; VBT, vaginal brachyterapy.
a Concomitant local and/or pelvic recurrence in 4 pts.
b VBT was added in 10 pts.
c VBT was added in 4 pts.
d Chemotherapy or no further treatment.
e With or without chemotherapy.
f Radiotherapy or no further treatment.
g With or without radiotherapy.
Table 5
Variables predictive of progression-free survival and overall survival.
a) Progression-free survival
Variables Pts 2-year PFS 5-year PFS P value
Age
b64 years 85 95.1% 83.4% 0.0025
N64 years 104 80.5% 66.0%
FIGO stage
Ib 159 89.3% 77.8% 0.035
II 30 76.1% 56.5%
FIGO grade
G2 108 89.4% 79.1% 0.1891
G3 81 85.5% 67.8%
Isthmus involvement
Yes 34 81.7% 60.1% 0.0271
Not 155 88.4% 77.5%
Type of hysterectomy
Type I 143 88.1 % 75.0% 0.9888
Type II 46 84.0 % 71.2%
Adjuvant treatment
Yes 151 88.9% 75.3% 0.2373
Not 38 80.1% 69.3%
Adjuvant radiotherapy
Not radiotherapya 46 83.8% 69.7% 0.2421
Radiotherapyb 143 88.3% 75.7%
Adjuvant chemotherapy
Not chemotherapyc 152 84.7% 71.3% 0.1612
Chemotherapyd 37 100.0% 86.0%
b) Overall survival
Variables Pts 2-year OS 5-year OS P value
Age
b64 years 85 100% 86.4% 0.0017
N64 years 104 89.5% 71.4%
FIGO stage
Ib 159 95.3% 83.1% 0.0103
II 30 85.9% 58.1%
FIGO grade
G2 108 93.9% 83.2% 0.2599
G3 81 93.5% 72.5%
Isthmus involvement
Yes 34 93.8% 61.2% 0.0280
Not 155 93.7% 82.9%
Type of hysterectomy
Type I 143 94.0% 78.2% 0.7339
Type II 46 92.6% 79.2%
Adjuvant treatment
Yes 151 94.3% 80.4% 0.2030
Not 38 91.0% 71.6%
Adjuvant radiotherapy
Not radiotherapya 46 92.8% 76.8% 0.4512
Radiotherapyb 143 94.0% 79.1%
Adjuvant chemotherapy
Not chemotherapyc 152 92.1% 75.6% 0.1619
Chemotherapyd 37 100.0% 92.3%
Legend: Pts, patients; PFS, progression-free survival, OS, overall survival.
a Chemotherapy or no further treatment.
b With or without chemotherapy.
c Radiotherapy or no further treatment.
d With or without radiotherapy.
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These two adjuvant treatments obtained similar results in terms of
vaginal recurrence rates, loco-regional relapse rates, distant metastasis
rates, disease-free survival and overall survival, but the incidence of
acute grade 1–2 gastrointestinal toxicity was significantly lower in the
VBT arm than in the EBRT arm (12.6% versus 53.8%). Therefore VBT
could be the adjuvant treatment of choice in this clinical setting.
Four randomized trials compared adjuvant platinum based chemo-
therapy to radiotherapy in high-risk endometrial cancer [22,23,29,30].
The pooled data meta-analyses showed a significant improvement in
terms of progression-free survival (HR = 0.80; 95%CI = 0.66–0.97)
and overall survival (HR= 0.76, 95% CI= 0.62–0.92) for chemotherapy
arm [24]. The HR for death was the same if the analysis excluded the
trial enrolling carcinosarcomas [30]. However, GOG122 included
patients with stage III–IV endometrial cancer with residual disease b2
cm [29]. The advantage in overall survival for chemotherapy arm was
lost if this trial was omitted from the analysis [24]. The GIGOC trial,
which enrolled 345 patients with high-risk endometrioid carcinoma
(FIGO stage [1988] Ic G3, IIa–b G3 with myometrial invasion N50%,
stage III disease), showed that EBRT delayed local relapses and chemo-
therapy delayed metastases but these trends did not achieve statistical
significance [22]. No separate analysis was performed in the subset of
the 90 women with stage Ic (FIGO 1988) disease and in the subset of
the 31 women with stage II disease. The Japanese GOG study, which
included 385 women with intermediate- and high-risk endometrioid
carcinoma with more than 50% myometrial invasion, failed to detect
any difference in progression-free survival and overall survival between
chemotherapy and EBRT in the group of patients with FIGO stage Ic
(1988) G1–2 disease under 70 years old [23]. Conversely, chemotherapy
achieved a significantly better progression-free survival (83.8% versus.
66.2%, HR = 0.44; 95% CI = 0.20–0.97) and overall survival (89.7%
versus. 73.6%, HR = 0.24, 95% CI = 0.09–0.69) in patients with stage
Ic G3 disease over 70 years old or with stage II or IIIA disease (positive
cytology).
Themeta-analysis of five randomized trials comparing no additional
treatmentwith additional chemotherapy after hysterectomy and radio-
therapy for high-risk endometrial cancer showed that chemotherapy
reduced the risk of developing the first recurrence outside the pelvis
(RR = 0.79; 95% CI = 0.68–0.92), and achieved a small benefit in
progression-free survival (HR = 0.75, 95% CI = 0.64–0.89) and overall
survival (HR= 0.74, 95% CI= 0.64–0.89) [24,25,31,32]. The analysis of
pelvic recurrence rates was underpowered but the trend suggested that
chemotherapymight have anadded valuewhenusedwith radiotherapy
(RR = 0.48, 95% CI = 0.20–1.18) [24].
In the present series, tumor relapsed in 36 out of 189 (19.0%)
women, with high-risk stage Ib–II endometrioid-type endometrial can-
cer, and recurrent diseasewasmost often distant. Therefore, the control
of systemic dissemination appears to be crucial for the clinical outcome
of these patients. Distant or aortic failure rate was significantly lower in
patientswho received adjuvant platinum-based chemotherapy (with or
Fig. 1. Progression-free survival (a) and overall survival (b) by adjuvant chemotherapy.
Fig. 2. Progression-free survival (a) and overall survival (b) by adjuvant radiotherapy.
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without radiotherapy) compared with those who did not (2.7% ver-
sus 18.4%, p = 0.02). There was a trend for a better 5-year
progression-free survival and 5-year overall for the patients who
received adjuvant chemotherapy (with or without radiotherapy)
compared with those who did not (86.0% versus 71.3% and 92.3%
versus 75.6%, respectively). It is noteworthy of the 29 patients
who underwent sequential adjuvant platinum-based chemothera-
py and radiotherapy none developed local recurrence and only
one (3.4%) had distant recurrence.
These results are in agreement with those of a phase II Radiation
Therapy Oncology Group [RTOG] trial designed to assess the feasibility
and efficacy of adjuvant EBRT concurrent with cisplatin followed by
VBT and 4 cycles of platinum-paclitaxel based chemotherapy in pa-
tients with high-risk endometrial cancer (grade 2–3 with either N50%
myometrial invasion, cervical stromal invasion, or pelvic-confined
extra-uterine disease) [33]. In this study, that showed an acceptable
toxicity, there were no failures in the 17 patients with stage Ic–IIb
(1988) disease, while loco–regional and distant recurrences occurred
in 7.4% and 29.6%, respectively, of the 27 patients with stage III disease.
The combined therapy approach obtained excellent pelvic and distant
control rates in patients with uterine-confined endometrial cancer,
whereas patients with stage III disease still experienced a predominant
pattern of distant metastases. The importance of this combined
adjuvant treatment has been recently confirmed by a retrospective
Canadian study including 55 patients with early-stage, high-risk
endometrial cancer (two or more risk uterine factors: grade 3, N50%
myometrial invasion, or cervical stromal involvement), who received
3 or 4 cycles of carboplatin plus paclitaxel followed by pelvic radio-
therapy [34]. After a median follow-up of 27 months, only 4 patients
(7.3%) recurred, including three with distant recurrence and one with
a pelvic and para-aortic nodal recurrence. A historical cohort in which
none of the patients received adjuvant chemo-radiotherapy had a
29.4% recurrence rate, and therefore the HR for recurrence was 0.27
(95% CI = 0.02–4.11).
The strengths of this study are represented by the enrollment
criteria that included only a very well defined group of high-risk but
early-stage endometrioid-type endometrial cancer patients (which
have been grouped with lower risk patients in prior studies), by the
length of follow-up, and by the description of rate and pattern of
recurrence. The weaknesses of the investigation are represented by
the over 20 year period of the study during which adjuvant therapy
changed substantially, by the retrospective nature, by the very limited
number of aortic lymphadenectomies performed (although all patients
had histologically negative pelvic nodes and negative CT findings for
node aortic involvement), and by the lack of standardization in post-
operative treatment. In any case, our data appear to suggest that
adjuvant platinum-based chemotherapy reduces the risk of distant
recurrences in patients with high-risk, early-stage endometrioid-type
endometrial cancer, and that the sequential administration of adjuvant
chemotherapy and radiotherapy achieves an excellent local and distant
control of disease in these clinical settings.
Multicenter phase III-randomized trials (PORTEC-3, ENGOT-EN2-
DGCG/EORTC 55102) are currently investigating the efficacy of
platinum-based chemotherapy, with or without radiotherapy in
patients with high-risk endometrial cancer [35,36]. The PORTEC-3
study compares adjuvant radiotherapy versus adjuvant concomitant
and sequential radiotherapy and chemotherapy in patients with high-
risk endometrial cancer (stage Ib G3 disease with lymph vascular
space involvement, stage Ic–IIa G3 disease, stage IIb, IIIa or IIIc disease,
or stage Ib–III disease with serous or clear cell histology) [35]. ENGOT-
EN2-DGCG/EORTC 55102 compares postoperative chemotherapy
versus no further treatment in patients with stage I–II medium or high
risk endometrial cancer [36].
Chemotherapy or sequential chemotherapy and radiotherapy will
probably have a larger and larger use in the adjuvant treatment of
high-risk, early-stage endometrioid-type endometrial cancer.
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